<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765736</url>
  </required_header>
  <id_info>
    <org_study_id>ACCRU-GI-1611</org_study_id>
    <secondary_id>NCI-2018-02862</secondary_id>
    <secondary_id>ACCRU-GI-1611</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03765736</nct_id>
  </id_info>
  <brief_title>Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial</brief_title>
  <official_title>COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Academic and Community Cancer Research United</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial screens patients with colon or rectal cancer that has spread to other places in
      the body (metastatic) or cannot be removed by surgery (unresectable) for genetic mutations
      for recommendation to a molecularly assigned therapy. Identifying gene mutations may help
      patients enroll onto target companion trials that target these mutations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To perform blood-based genomic profiling on patients with treatment refractory metastatic
      colorectal cancer (CRC) to facilitate accrual to molecularly assigned therapies.

      II. To facilitate clinically annotated genomic analyses.

      OUTLINE:

      Patients submit blood samples for genetic testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">November 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients that enroll in the companion trial recommended by the Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy (COLOMATE) committee</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>This is defined as the total number of patients that enroll in the recommended companion trial divided by the total number of patients who have an actionable genomic profile. Will be presented as a point estimate along with a 95% confidence interval (by Wald asymptotic confidence limit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients who have an actionable genomic profile</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>This is defined as the total number of patients who have an actionable genomic profile divided by the total number of patients that are screened on the COLOMATE protocol. Will be presented as a point estimate along with a 95% confidence interval (by Wald asymptotic confidence limit).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metastatic Colon Adenocarcinoma</condition>
  <condition>Metastatic Rectal Adenocarcinoma</condition>
  <condition>Stage III Colon Cancer AJCC v8</condition>
  <condition>Stage III Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIA Colon Cancer AJCC v8</condition>
  <condition>Stage IIIA Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIB Colon Cancer AJCC v8</condition>
  <condition>Stage IIIB Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIC Colon Cancer AJCC v8</condition>
  <condition>Stage IIIC Rectal Cancer AJCC v8</condition>
  <condition>Stage IV Colon Cancer AJCC v8</condition>
  <condition>Stage IV Rectal Cancer AJCC v8</condition>
  <condition>Stage IVA Colon Cancer AJCC v8</condition>
  <condition>Stage IVA Rectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colon Cancer AJCC v8</condition>
  <condition>Stage IVB Rectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colon Cancer AJCC v8</condition>
  <condition>Stage IVC Rectal Cancer AJCC v8</condition>
  <condition>Unresectable Colon Adenocarcinoma</condition>
  <condition>Unresectable Rectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
    <description>Patients submit blood samples for genetic testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Undergo genetic testing</description>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
    <other_name>genetic analysis</other_name>
    <other_name>Genetic Examination</other_name>
    <other_name>Genetic Test</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of adenocarcinoma of the colon or rectum that is metastatic
             and/ or unresectable

          -  Progression, intolerance, or contraindication to a fluoropyrimidine (e.g., 5-
             fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal
             antibody (bevacizumab, ziv-aflibercept, or ramucirumab), and an anti-PD-1 monoclonal
             antibody (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins
             (dMMR) or is microsatellite instability-high (MSI-H)

          -  For patients with KRAS and NRAS wild-type tumors, progression, intolerance, or
             contraindication to an anti-EGFR monoclonal antibody (cetuximab or panitumumab)

               -  Note: If tissue is known to be positive for HER2 expression (IHC 3+) or the tumor
                  has ERBB2 (HER2) amplification detected by a Clinical Laboratory Improvement Act
                  (CLIA)-certified assay, prior treatment with anti-EGFR therapy is not required

          -  At least one site of disease that is measurable by Response Evaluation Criteria in
             Solid Tumors (RECIST) criteria (version 1.1) that has not been previously irradiated;
             if the patient has had previous radiation to the target lesion(s), there must be
             evidence of progression since the radiation

          -  Life expectancy &gt;= 3 months per estimation of investigator

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Capable of understanding and complying with the protocol requirements and has signed
             the informed consent document

          -  Willing to provide blood sample for screening purposes

               -  NOTE: Guardant360 testing completed =&lt; 60 days prior to registration will be
                  accepted.

        Exclusion Criteria:

          -  Evidence within the last 3 years of another malignancy which required systemic
             treatment. EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix, or
             localized prostate cancer with a current PSA of &lt; 1.0mg/dL on 2 successive
             evaluations, at least 90 days apart, with the most recent evaluation no more than 4
             weeks prior to registration

          -  Unable or unwilling to abide by the study protocol or cooperate fully with the
             investigator or designee

          -  History of solid organ transplantation

          -  Pregnant or planning to become pregnant within the next 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H Strickler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic and Community Cancer Research United</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referrals Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Tanios S. Bekaii-Saab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7459</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Shumei Kato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carryl Du Bois</last_name>
      <phone>323-865-3084</phone>
      <email>Carryl.DuBois@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Heinz-Josef Lenz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Kearns</last_name>
      <phone>253-831-3423</phone>
      <email>Karen.Kearns@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Jun Gong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7453</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin A. Weinberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KJ Lee</last_name>
      <phone>404-778-3173</phone>
      <email>kyungjong.lee@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Christina S. Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7458</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel V. Catenacci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7450</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kimmie Ng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referrals Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Joleen M. Hubbard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7462</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Katrina S. Pedersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7457</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Cercek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Amara</last_name>
      <phone>919-668-1861</phone>
      <email>Anthony.amara@duke.edu</email>
    </contact>
    <investigator>
      <last_name>John H. Strickler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Derzic</last_name>
      <phone>412-330-6263</phone>
      <email>Karen.derzic@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Gene G. Finley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7461</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen K. Ciombor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7456</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Benny Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7449</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Federico Augusto H. Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

